You are currently viewing Use of Rhu-GM-CSF in pulmonary tuberculosis
rhugm csf

Use of Rhu-GM-CSF in pulmonary tuberculosis

Secondary infections related to neutropenia and functional defects of phagocytes are common outcomes in cancer-treated patients. Hematopoietic colony-stimulating factors (CSFs) have been introduced into clinical practice as additional adjuvant measures that may reduce the incidence of infectious complications in patients with cancer and neutropenia.

The aim of this study was to determine the role of granulocyte/macrophage (GM)-CSF and granulocyte (G)-CSF in enhancing in vivo human neutrophil function. A luminol-dependent chemiluminescence assay was developed to evaluate whether neutropenia has to do with the ability of neutrophils to perform repair function. A single dose of 5 µg G-CSF kg(-1) day(-1) [recombinant human (RHU) G-CSF; filgrastim] or 250 µg GM-CSF m(-2) day(-1) (rHu GM-CSF; molgramostim) administered subcutaneously once daily to 12 metastatic cancer patients being treated with various cytotoxic regimens Was. All injections of CSF were given after the onset of neutropenia and continued until the occurrence of a complete neutrophil recovery. rHu GM-CSF and rHu G-CSF administered once a day at 250 µg m(-2) day (-1) and 5 µg kg(-1) day (-1),

rhugm brucells
rhugm brucells

Materials and methods

study population. Patients were included if they presented with (1) a clinical and radiological picture consistent with active pulmonary TB, and vigorously according to the acid-fast-bacilli (AFB) method in two consecutive sputum smears. were positive smears (3 plus); (2) were between 18 and 50 years of age; (3) had no history of previous TB treatment; and (4) had leukocyte counts below 25,000/mm at 3 admission. Patients were excluded if they (1) presented with any serious concomitant diseases, such as severe pulmonary dysfunction, renal, cardiac, hematological or liver disease; (2) had severe dermatological lesions above grade 3 on the WHO score system; (3) were pregnant or lactating women; (4) had a history of alcohol abuse, had diabetes mellitus, had mental disorders, were HIV or HTLV-I/II positive; (5) were receiving immunosuppressive treatment; or (6) could not provide informed consent or could not be followed after a period of hospitalization. Administration of previous or concomitant drugs such as antimycobacterial drugs was not permitted during the study period.

All patients gave written informed consent before entering the study.

Randomization and study treatment. After diagnosis of tuberculosis, patients meeting all admission criteria were hospitalized for at least the first two weeks to allow a better clinical assessment of tolerability. Patients were randomized to take either rhu-GM-CSF 125 µg/m2/dose) twice a week for four weeks, or a placebo, both supplied by Immunex Corporation. Neither the doctor nor the patient knew what medicine they were taking. In addition to challenge treatment, all patients weighing more than 45 kg to take rifampin (600 mg/day) + isoniazid (400 mg/day) daily for six months and pyrazinamide (2000 mg/day) for the initial two months was scheduled. Patients weighing less than 45 kg were prescribed 450 mg/day rifampin + 300 mg/day isoniazid for six months and 1500 mg/day pyrazinamide for the initial two months.

Colony-stimulating factors (CSFs) are secreted glycoproteins that bind to receptor proteins on the surfaces of hemopoietic stem cells, thereby activating intracellular signaling pathways that allow cells to grow and develop into a specific type of blood cell (usually white blood cells). can cause the difference. .

Features and Specifications:

  • Custom packaging and sizes are available
  • Single-use syringe configuration
  • Lyophilized or liquid format
  • Pharmaceutical grade
  • Sterile-filled
  • Custom biological activity assays available



Mouse GM-CSF ELISA Kit, 96 tests, Quantitative

MGM-CSF-100 1 kit
EUR 482

Human GM-CSF ELISA Kit, 96 tests, Quantitative

HGM-CSF-100 1 kit
EUR 482

PRE-GMP rHu GM-CSF, Molgramostim-Leukoma

04-RHUGM-CSF-7A10 300 µg
EUR 385
Description: Recombinant human GM-CSF produced in E.coli is a single, non-glycosylated, polypeptide chain containing 127 amino acids, two pairs of disulfide bonds and having a molecular mass of approximately 14.5kD.


ELA-E1111r 96 Tests
EUR 886

Mycobacterium tuberculosis (M. tuberculosis) Antibody

abx415707-1ml 1 ml
EUR 606


E21-002 10ug
EUR 343


E21-003 10ug
EUR 343


E21-417 10ug
EUR 343


E21-J46 10ug
EUR 343

CSF Tubes

213361-(V100) 100 tubes
EUR 1688

CSF Tubes

213361-(V25) 25 tubes
EUR 505

CSF Tubes

213361-(V6) 6 tubes
EUR 186.5

CSF Tubes

abx290032-100tubes 100 tubes
EUR 1957

CSF Tubes

abx290032-25tubes 25 tubes
EUR 662

CSF Tubes

abx290032-6tubes 6 tubes
EUR 314

Recombinant Mouse M-CSF/CSF-1 Protein

RP01216 10 μg
EUR 202

Recombinant human M-CSF/CSF-1 Protein

RP01221 10 μg
EUR 230


ELA-E0042r 96 Tests
EUR 886

G-CSF, Human

HY-P7015 100ug
EUR 946

GM-CSF, Human

HY-P7016A 50ug
EUR 441

Leave a Reply